title: Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.
abstract: Posaconazole (PCZ) is given at 200 mg three times daily as a fungal prophylaxis in neutropenic hematologic malignancy patients. A relationship between exposure, plasma concentration, and efficacy is suggested. The objectives of this prospective study were to analyze the PCZ plasma concentration in hematology adults at high risk of developing invasive fungal infections (IFIs), and factors that could have an impact on the PCZ plasma concentration. PCZ plasma concentrations were measured after 2, 7, 10, 14, and 21 days of PCZ prophylaxis. Factors such as gender, age, body weight, posology, treatment duration, mucositis, proton pump inhibitor (PPI) use, and food intake were studied. Sixty-three patients were included, with a median age of 52 years (range 17-70) and a median weight of 75 kg (range 47-150). The median PCZ plasma concentration of the 63 patients ranged from 0.42 to 0.48 mg/L. At day 2, 30% of PCZ plasma concentration were under 0.35 mg/L, and at day 7, 74% were <0.70 mg/L. PCZ plasma concentrations were not affected by gender, age, body weight, or treatment duration. We found that food intake had a high influence on PCZ plasma concentrations (p = 0.0049). PCZ was well tolerated. One patient has developed a probable IFI, probably related to a low exposure to PCZ. PCZ therapeutic drug monitoring (TDM) is essential in order to early detect patients with low concentrations, to assess the etiology of such results, and to decide on the treatment strategy to apply.
authors: Department of Medical Pharmacology and Toxicology, University Hospital of Montpellier, Montpellier, France. c-eiden@chu-montpellier.fr
authors: C
authors: C
authors: Eiden
authors: J C
authors: JC
authors: Meniane
authors: H
authors: H
authors: Peyrière
authors: S
authors: S
authors: Eymard-Duvernay
authors: G
authors: G
authors: Le Falher
authors: P
authors: P
authors: Ceballos
authors: N
authors: N
authors: Fegueux
authors: M
authors: M
authors: Cociglio
authors: J
authors: J
authors: Reynes
authors: D
authors: D
authors: Hillaire-Buys
references: Pharmacotherapy. 2008 Oct;28(10):1223-32
references: 18823218
references: N Engl J Med. 2007 Jan 25;356(4):348-59
references: 17251531
references: Antimicrob Agents Chemother. 2007 Mar;51(3):812-8
references: 17210771
references: Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95
references: 12936975
references: Clin Infect Dis. 2007 Jan 1;44(1):2-12
references: 17143808
references: Int J Antimicrob Agents. 2011 Mar;37(3):266-9
references: 21236645
references: Clin Pharmacokinet. 2005;44(2):211-20
references: 15656699
references: Antimicrob Agents Chemother. 2006 Jun;50(6):1993-9
references: 16723557
references: Ann Pharmacother. 2008 Oct;42(10):1429-38
references: 18713852
references: Antimicrob Agents Chemother. 2009 Dec;53(12):5224-9
references: 19752284
references: Clin Pharmacol Ther. 2010 Jul;88(1):115-9
references: 20505665
references: Antimicrob Agents Chemother. 2009 Mar;53(3):958-66
references: 19075045
references: J Clin Pharm Ther. 2009 Jun;34(3):301-11
references: 19646076
references: N Engl J Med. 2007 Jan 25;356(4):335-47
references: 17251530
references: Antimicrob Agents Chemother. 2009 Jan;53(1):24-34
references: 18955533
references: Br J Clin Pharmacol. 2004 Feb;57(2):218-22
references: 14748822
references: Antimicrob Agents Chemother. 2009 May;53(5):2223-4
references: 19258264
references: Pharmacotherapy. 2007 Dec;27(12):1627-36
references: 18041883
references: Clin Infect Dis. 2008 Jun 15;46(12):1813-21
references: 18462102